BioCryst Pharmaceuticals | BCRX - Assets


BioCryst Pharmaceuticals reported $591.07M in Assets for its fiscal quarter ending in September of 2026.





Assets Change Date
Alnylam Pharmaceuticals USD 7.99B 2.44B Sep/2026
BioCryst Pharmaceuticals USD 591.07M 33.22M Sep/2026
Chugai Pharma JPY 2.37T 75.59B Sep/2026
Daiichi Sankyo JPY 4.26T 144.08B Sep/2026
DBV Technologies USD 215.4M 7.8M Sep/2026
Enanta Pharmaceuticals USD 329.5M 48.77M Dec/2025
Gilead Sciences USD 51.41B 2.05B Sep/2026
GlaxoSmithKline GBP 71.7B 9.96B Sep/2026
Glaxosmithkline GBP 71.7B 8.83B Sep/2026
Incyte USD 7.29B 585.39M Sep/2026
Ionis Pharmaceuticals USD 2.91B 81.91M Sep/2026
Karyopharm Therapeutics USD 131.42M 23M Mar/2026
Neurocrine Biosciences USD 5.63B 268.3M Sep/2026
Novavax USD 888M 67.57M Sep/2026
PTC Therapeutics USD 3.21B 42.76M Sep/2026
Regeneron Pharmaceuticals USD 44.41B 2.67B Sep/2026
Roche Holding CHF 98.2B 2.5B Jun/2026
Sarepta Therapeutics USD 3.17B 22.45M Sep/2026
Ultragenyx Pharmaceutical USD 1.19B 77M Sep/2026
Vertex Pharmaceuticals USD 32.74B 5.31B Sep/2026